Centre for DNA Fingerprinting and Diagnostics (CDFD)

Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome.

In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world.

Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large.

We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and bio-therapeutics in Hyderabad, India. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella.

Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.

Our significant R&D investments have yielded several breakthroughs including the world’s 1st Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal).Rotavirus vaccine from a naturally attenuated strain,Typhoid Conjugate vaccine.

Transparency and openness are central to our DNA. An uncompromising commitment to integrity differentiates us. Our clinical trials are known for their rigor and breadth. We also adopt the most comprehensive data integrity procedures to ensure that we capture, store and report data accurately. We are committed to provide affordable and innovative vaccines for healthier lives.

Bharat Biotech launched India’s first recombinant Epidermal Growth Factor (REGEN-D®) to combat diabetic foot ulcers, burns.

Typbar TCV® is the world’s first clinically proven conjugate Typhoid vaccine and received WHO-Prequalification in January 2018.

ROTAVAC® was India’s first and largest efficacy clinical trial on vaccines and Rotavac® received WHO-Prequalification in January 2018.

Bharat Biotech Launches ROTAVAC 5D®- Lowest dose volume
Rotavirus vaccine - ROTAVAC in the world launched in December 2019.

COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech.

BIONEEDS INDIA PRIVATE LIMITED is a Bangalore based Contract Research Organization providing Integrated Discovery, Development and Regulatory Services to Pharmaceutical,
Biopharmaceutical, Agrochemical, Industrial chemical, Herbal/Nutraceutical and Medical device companies.

Accreditation/Certifications
• National GLP Compliance Monitoring Authority (NGCMA), Dept. of Science and Technology, Government of India
• Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forests and Climate Change, GOI.
• State Drug Controller as a Government approved Drug Testing Laboratory for carrying out tests on Drugs / Cosmetics and
• Raw Materials used in their manufacture on behalf of licensees for manufacture for sale of drugs / cosmetics
• Review Committee on Genetic Manipulation (RCGM), department of biotechnology, GOI to conduct experiments on animals for DNA or Genetically modied resources
• Bioneeds is AAALAC certified for laboratory animal care
• Bioneeds’ in-house R & D unit is recognised by Department of Scientic and Industrial Research (DSIR)
• ISO 17025 certified for Biological evaluation of Medical Devices
• Bioneeds has best-in-class infrastructure equipped with state-of-the-art facilities with 2,50,000 sqft built-up area.
• Vivarium with 85 exclusive animal rooms built as per international standards
• Cutting edge Drug Discovery and Development Labs to support Medicinal chemistry, Biology, In vivo Pharmacology,
• Toxicology, Custom synthesis, Process R&D, cGMP manufacturing, Formulation and Analytical development services

A frontier company in medical genetics research

DNA Link is currently in collaboration with Korea’s most renowned clinical research specialists studying genetic effects of various diseases including diabetes, cardiovascular disease, cancer, atopy, and digestive diseases.

Recent advancements in genomic research technology have enabled rapid analysis of whole genomes. Our current research projects utilize this technology to identify relationships between diseases and genomic content.

In the past, genetic disease studies were conducted using a finite set of candidate genes as targets for research. While the results were valuable, the success of this approach was limited because diseases can depend on multiple factors, genetic and environmental. Modern genetic research methodologies take a more extended approach, considering the entire human genome to search for potential disease markers.

In addition to identifying disease-related genes, DNA Link is working to develop disease diagnostic systems as well as personalized treatment methods. Using DNA Chip and Next Generation Sequencing technologies, we are currently developing cancer diagnostic systems by identifying common variants in DNA copy numbers for various cancers including lung cancer and breast cancer

DNAFORM offers innovative technology platforms for genome and transcriptome analysis. These include Cap-trapped full-length cDNA cloning, high-throughput expression profiling and promoter identification by next generation sequencing including genome annotation (Cap Analysis Gene Expression or CAGE), and point of care genotyping by SmartAmp. All our technologies gained rapid global recognition from outstanding publication records in leading scientific journals like Nature, Science, Nature Methods, and Nature Genetics. Moreover, DNAFORM is a leading clone distributor in particular offering resources from the RIKEN FANTOM Projects.